Who are Podofilox Gel 0.5%'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Adcetris, Halaven, Jevtana Kit, Taxol, Taxol, VIN.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/podofilox-gel-0-5.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Podofilox Gel 0.5% — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Podofilox Gel 0.5% (Podofilox Gel 0.5%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimitotic agent. Area: Oncology.

phase 3 Antimitotic agent Tubulin Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Podofilox Gel 0.5% (Podofilox Gel 0.5%) — Dermax SA. Podofilox is a plant-derived antimitotic agent that inhibits cell division.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Podofilox Gel 0.5% TARGET	Podofilox Gel 0.5%	Dermax SA	phase 3	Antimitotic agent	Tubulin
Adcetris	brentuximab-vedotin	Pfizer	marketed	CD30-directed Immunoconjugate [EPC]	Tubulin beta	2011-01-01
Halaven	ERIBULIN	Eisai	marketed	Microtubule Inhibitor	Tubulin beta	2010-01-01
Jevtana Kit	cabazitaxel	Accord Hlthcare	marketed	Microtubule Inhibitor	Tubulin beta	2010-01-01
Taxol	paclitaxel	Pfizer	marketed	Microtubule Inhibitor [EPC]	Tubulin beta-3 chain	1992-01-01
Taxol	nab-paclitaxel	Pfizer	marketed	Microtubule Inhibitor	Tubulin beta-3 chain	1992-01-01
VIN	VIN	Italian Sarcoma Group	marketed	Vinca alkaloid; microtubule inhibitor	β-tubulin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-06-10 — Jevtana Kit · 7241907*PED · Compound · US
2026-08-13 — Taxol · 8034375 · Method of Use · US
2026-08-13 — Taxol · 8034375 · US
2026-08-21 — Taxol · 9101543*PED · US
2026-08-21 — Taxol · 8268348*PED · Compound · US
2026-08-21 — Taxol · 7758891*PED · Compound · US
2026-08-21 — Taxol · 9101543*PED · Compound · US
2026-08-21 — Taxol · 8268348*PED · US
2026-08-21 — Taxol · 7758891*PED · US
2027-02-13 — Taxol · 8034375*PED · Compound · US
2027-02-13 — Taxol · 8034375*PED · US
2030-10-27 — Jevtana Kit · 12453712 · Method of Use · US
2030-10-27 — Jevtana Kit · 10583110 · Method of Use · US
2030-10-27 — Jevtana Kit · 10716777 · Method of Use · US
2030-10-27 — Jevtana Kit · 8927592 · Method of Use · US
2031-04-27 — Jevtana Kit · 12453712*PED · Compound · US
2031-04-27 — Jevtana Kit · 8927592*PED · Compound · US
2031-04-27 — Jevtana Kit · 10583110*PED · Compound · US
2031-04-27 — Jevtana Kit · 10716777*PED · Compound · US
2032-03-04 — Taxol · 9393318 · Method of Use · US
2032-03-04 — Taxol · 9597409 · US
2032-03-04 — Taxol · 9393318 · US
2032-03-04 — Taxol · 9597409 · Method of Use · US
2032-09-04 — Taxol · 9393318*PED · Compound · US
2032-09-04 — Taxol · 9597409*PED · Compound · US
2032-09-04 — Taxol · 9393318*PED · US
2032-09-04 — Taxol · 9597409*PED · US
2034-01-12 — Taxol · 9511046 · US
2034-01-12 — Taxol · 9511046 · Method of Use · US
2034-07-12 — Taxol · 9511046*PED · US

Sponsor landscape (Antimitotic agent class)

Dermax SA · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Podofilox Gel 0.5% — Competitive Intelligence Brief. https://druglandscape.com/ci/podofilox-gel-0-5. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab